State-of-the-Art Mechanisms of Drug Resistance to Targeted Therapy in Cancers
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 25 November 2024 | Viewed by 1082
Special Issue Editors
Interests: drug resistance; ABC transporters; natural products; nanomaterials; tyrosine kinase inhibitors
Special Issue Information
Dear Colleagues,
Drug resistance is an overwhelming challenge in cancer treatment, particularly in the context of targeted therapies. Targeted therapies are designed to inhibit specific proteins or pathways that are critical for tumour growth and progression. While these therapies have been extensively adopted as the standard and preferred regimens, the development of drug resistance often limits their long-term effectiveness. Genetic alterations, bypass signalling, altered drug transport/metabolism, epigenetic changes, tumour heterogeneity, the tumour microenvironment, and adaptive evolution all contribute to tumour resistance.
It is crucial to note that these mechanisms can vary across different cancer types and even among individual patients. Additionally, cancer cells can employ multiple mechanisms simultaneously or develop new resistance mechanisms over time, further complicating treatment strategies. Overcoming drug resistance remains a significant area of research, and ongoing efforts are focused on identifying and targeting these mechanisms in order to develop novel therapeutic strategies and enhance cancer treatment outcomes.
This Special Issue will address subjects related to recent progress on mechanisms of drug resistance to targeted therapy in cancer therapy. It will offer a comprehensive understanding of current progress in the field and highlight perspectives and challenges for the future.
Dr. Yan Li
Dr. Johnson Liu
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- multidrug resistance (MDR)
- targeted therapies
- ABC transporters
- biomarkers
- cancer stem-like cells
